XORTX Therapeutics Inc. submitted a Form 6-K report to the SEC on November 14, 2024, disclosing its financial statements and analysis for the nine months ending September 30, 2024. The filing includes management discussion and certification from the CEO and CFO, indicating no significant changes or events reported beyond regular financial updates.